What Precision Biosciences, Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 3 | 6 |
| Sells | 0 | 11 |
| Total trades | 3 | 41 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 4,744 | 474,642 |
| Disposed | 0 | 113,001 |
| Net activity | +4,744 | +361,641 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Frankel Stanley | Director | Sep 28 | Open-market buy · P | +1,000 | $6.00 | +$6K | 41,478 |
| Brown Melinda | Director | Sep 25 | Open-market buy · P | +1,135 | $6.27 | +$7.12K | 45,481 |
| Germano Geno J | Director | Sep 25 | Open-market buy · P | +2,609 | $6.28 | +$16.4K | 47,492 |
| Germano Geno J | Director | May 20 | Exercise / conversion · M | +21,000 | — | — | 44,883 |
| Pire Shari Lisa | Director | May 20 | Exercise / conversion · M | +21,000 | — | — | 35,028 |
| Brown Melinda | Director | May 20 | Exercise / conversion · M | +21,000 | — | — | 44,346 |
| Buehler Kevin | Director | May 20 | Exercise / conversion · M | +21,000 | — | — | 49,137 |
| Frankel Stanley | Director | May 20 | Exercise / conversion · M | +21,000 | — | — | 40,478 |
| Smith J. Jefferson | Chief Research Officer | Feb 18 | Open-market sale · S | −4,925 | $3.84 | −$18.9K | 121,926 |
| Kelly John Alexander | Chief Financial Officer | Feb 18 | Open-market sale · S | −8,149 | $3.84 | −$31.3K | 125,883 |
| Amoroso Michael | President and CEO | Feb 18 | Open-market sale · S | −20,559 | $3.84 | −$78.9K | 243,392 |
| Scimeca Dario | General Counsel and Secretary | Feb 18 | Open-market sale · S | −4,925 | $3.84 | −$18.9K | 56,457 |
| Smith J. Jefferson | Chief Research Officer | Feb 17 | Exercise / conversion · M | +16,667 | — | — | 126,851 |
| Kelly John Alexander | Chief Financial Officer | Feb 17 | Exercise / conversion · M | +27,584 | — | — | 134,032 |
| Amoroso Michael | President and CEO | Feb 17 | Exercise / conversion · M | +67,797 | — | — | 263,951 |
| Scimeca Dario | General Counsel and Secretary | Feb 17 | Exercise / conversion · M | +16,667 | — | — | 61,382 |
| Amoroso Michael | President and CEO | Jan 22 | Open-market sale · S | −34,799 | $4.17 | −$145K | 196,154 |
| Smith J. Jefferson | Chief Research Officer | Jan 21 | Open-market sale · S | −10,200 | $4.03 | −$41.1K | 110,184 |
| Smith J. Jefferson | Chief Research Officer | Jan 21 | Exercise / conversion · M | +16,219 | — | — | 120,384 |
| Kelly John Alexander | Chief Financial Officer | Jan 21 | Open-market sale · S | −15,213 | $4.03 | −$61.3K | 106,448 |
Loading...
